Business Context and Reporting Period
This Form 8-K Current Report was filed by Prime Medicine, Inc. on April 7, 2026. The filing discloses the appointment of a new Chief Financial Officer (CFO) and Principal Financial Officer, effective April 16, 2026, and the concurrent transition of the former Principal Financial Officer.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation and employment terms.
- New CFO Base Salary: $495,000 annually.
- Sign-on Bonus: $40,000 one-time payment.
- Target Annual Bonus: 40% of base salary.
- Time-Based Stock Options: 800,000 shares (25% vesting at one year, remainder monthly over 36 months).
- Milestone-Based Stock Options: 100,000 shares (vesting upon achievement of agreed milestones).
Material Changes
The primary material change is the leadership transition in the finance function:
- Appointment: Svetlana Makhni appointed as CFO and Principal Financial Officer, effective April 16, 2026.
- Departure: Allan Reine, M.D., steps down as Principal Financial Officer for Section 16 reporting purposes effective April 16, 2026, while retaining his role as Chief Executive Officer.
Outlook, Risks, and Unusual Items
Management Commentary and Compensation Structure: The filing details significant severance protections for the new CFO:
- Standard Termination (Without Cause/Good Reason): Entitlement to 9 months of base salary plus 0.75x target bonus, paid over 9 months, plus COBRA health coverage support.
- Change in Control Termination: Entitlement to a lump sum of 12 months of base salary plus 1.0x target bonus, full vesting of time-based equity awards, and performance-based awards vesting at target.
Risks and Contingencies: The filing notes that severance payments are contingent upon the execution of a fully effective separation agreement, including a release of claims and, at the Company's discretion, a one-year non-competition agreement.
Investor Verification Checklist
- Verify the exact closing stock price on the grant date to determine the exercise price for the 900,000 total stock options granted.
- Review the attached Employment Agreement (Exhibit 10.1) for specific definitions of "Cause," "Good Reason," and "Change in Control."
- Confirm the specific performance milestones attached to the 100,000 milestone-based stock options.
- Monitor future filings for the impact of this executive transition on the company's financial reporting and strategic direction.